{"product_id":"understanding-your-blood-pressure-goal-a-patients-guide-to-hypertension-treatment-targets","title":"Understanding Your Blood Pressure Goal: A Patient's Guide to Hypertension Treatment Targets","description":"\u003cp\u003eManaging blood pressure is one of the most important things you can do to protect your heart, brain, and kidneys. This article explains what blood pressure goal is right for you, how your doctor should measure your blood pressure to get accurate readings, and what the latest research—including the landmark SPRINT trial—shows about the benefits of more intensive blood pressure lowering. It covers why your personal risk level matters, which patients benefit from lower blood pressure targets, and important safety considerations, all explained in plain language with the full scientific data included.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Your Blood Pressure Goal: A Patient's Guide to Hypertension Treatment Targets\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eIntroduction: Why Blood Pressure Treatment Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#measurement\"\u003eHow Blood Pressure Should Be Measured (And Why It Matters)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#risk\"\u003eUnderstanding Risk: Absolute vs. Relative Risk\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#higher-risk\"\u003eBlood Pressure Goals for Higher-Risk Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#sprint\"\u003eThe SPRINT Trial: Key Evidence for Intensive Blood Pressure Control\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#sprint-results\"\u003eWhat the SPRINT Results Show\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Research Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eRoutine office blood pressure readings can be 5–15 mmHg higher than standardized methods, so doctors prefer the latter for setting targets.\u003c\/li\u003e\n\u003cli\u003eTreatment decisions are based on absolute risk reduction: high-risk patients gain more from intensive blood pressure lowering than low-risk patients.\u003c\/li\u003e\n\u003cli\u003eIn the SPRINT trial, targeting systolic pressure below 120 mmHg reduced cardiovascular events and death in high-risk non-diabetic adults.\u003c\/li\u003e\n\u003cli\u003eIntensive blood pressure lowering may increase acute kidney injury, fainting, and low sodium, but most issues resolve and serious falls were not increased.\u003c\/li\u003e\n\u003cli\u003eHigher-risk patients—including those with heart disease, diabetes, CKD, or age over 65—may benefit from lower goals, but shared decision-making with your doctor is essential.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eIntroduction: Why Blood Pressure Treatment Matters\u003c\/h2\u003e\n\u003cp\u003eHigh blood pressure (hypertension) is one of the most common health conditions worldwide. In fact, treating high blood pressure is one of the most frequent reasons that non-pregnant adults visit their doctor's office, and it's among the top reasons people take prescription medications. This topic is reviewed by experts at UpToDate, a leading physician reference used by doctors around the world.\u003c\/p\u003e\n\u003cp\u003eThis article covers two key questions for anyone living with hypertension: When should blood pressure medication be started, and what blood pressure number should you aim for? The answers depend on several factors, including how your blood pressure is measured and your personal risk for future heart problems (cardiovascular events) such as heart attacks, strokes, and heart failure.\u003c\/p\u003e\n\u003cp\u003eYour doctor will consider many other aspects of hypertension, including risk factors, diagnosis, proper measurement technique, lifestyle changes (diet, salt restriction, weight loss, and exercise), and which specific medication is best for you. These are all important pieces of the puzzle, but this article focuses specifically on the blood pressure target you should be aiming for.\u003c\/p\u003e\n\n\u003ch2 id=\"measurement\"\u003eHow Blood Pressure Should Be Measured (And Why It Matters)\u003c\/h2\u003e\n\u003cp\u003eOne of the most important things to understand is that blood pressure targets depend heavily on \u003cem\u003ehow\u003c\/em\u003e your blood pressure is measured. The method used can make a big difference in the numbers you see.\u003c\/p\u003e\n\u003cp\u003eThere are two broad categories of blood pressure measurement described by the experts:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Routine\" (typical\/casual) office blood pressure\u003c\/strong\u003e – This is the non-preferred method that is most commonly used worldwide. It involves measuring blood pressure once at the beginning of an office visit, often with the care provider in the room, and usually without proper patient preparation (such as having an empty bladder, sitting quietly with both feet on the floor for 3–5 minutes, not talking during the measurement, or using the correct cuff size). Because of the lack of standardization, these readings can vary widely from office to office and even between providers. This method is faster and easier, which is why it's used 90% of the time.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Non-routine\" standardized methods (the preferred approach)\u003c\/strong\u003e – These four methods provide readings that are much closer to your true daytime blood pressure and were used in nearly all major outcome trials in hypertension:\n    \u003col\u003e\n      \u003cli\u003e\n\u003cstrong\u003eStandardized office-based measurement\u003c\/strong\u003e – This doesn't require special equipment (it can be done manually or with an automated device), but it \u003cem\u003edoes\u003c\/em\u003e require proper patient preparation and proper technique, including resting quietly for several minutes before the reading.\u003c\/li\u003e\n      \u003cli\u003e\n\u003cstrong\u003eAutomated oscillometric blood pressure monitoring (AOBPM)\u003c\/strong\u003e – This uses a specialized device programmed to take and average multiple consecutive readings after you've rested in a seated position for about five minutes. The care provider starts the machine and then leaves the room. This technique was used in the famous SPRINT trial (discussed below).\u003c\/li\u003e\n      \u003cli\u003e\n\u003cstrong\u003eHome blood pressure monitoring\u003c\/strong\u003e – You measure your own blood pressure at home with an automated device that has been checked for accuracy in the doctor's office. Typically, multiple readings are taken daily over several consecutive days and then averaged. A common approach is to take 2–4 readings daily for 5–7 days before your clinic visit.\u003c\/li\u003e\n      \u003cli\u003e\n\u003cstrong\u003eAmbulatory blood pressure monitoring (ABPM)\u003c\/strong\u003e – You wear a device for 24 hours that takes blood pressure readings automatically every 15–30 minutes during the day and every 30–60 minutes during sleep. This gives a complete picture of your blood pressure over a full day and night.\u003c\/li\u003e\n    \u003c\/ol\u003e\n  \u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhy does this matter so much? Because on average, routine office measurements are \u003cstrong\u003e5 to 15 mmHg higher\u003c\/strong\u003e than non-routine standardized measurements. This gap exists because the \"white coat\" effect (blood pressure rising due to anxiety about being in a medical setting) is often present, and because routine measurements are taken without proper preparation and technique.\u003c\/p\u003e\n\u003cp\u003eSome studies have shown even more dramatic differences between the two methods. However, it's critical to understand that this average difference applies to \u003cem\u003epopulations\u003c\/em\u003e, not necessarily to \u003cem\u003eyou individually\u003c\/em\u003e. Some people don't experience a white coat effect at all, so there is some uncertainty when setting goals based on the measurement method. The takeaway is simple: ideally, treatment decisions should be based on one of the preferred, standardized methods rather than a casual reading taken at the start of an office visit.\u003c\/p\u003e\n\n\u003ch2 id=\"risk\"\u003eUnderstanding Risk: Absolute vs. Relative Risk\u003c\/h2\u003e\n\u003cp\u003eOne of the most important concepts in blood pressure management is the difference between \u003cem\u003erelative\u003c\/em\u003e risk reduction and \u003cem\u003eabsolute\u003c\/em\u003e risk reduction. This sounds technical, but it's actually quite intuitive once explained.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRelative risk reduction\u003c\/strong\u003e means the percentage by which a treatment lowers your chances of an event compared with not taking the treatment. \u003cstrong\u003eAbsolute risk reduction\u003c\/strong\u003e is the actual percentage-point difference in your personal risk. The experts explain that treatment decisions should be made based on the absolute benefits and harms, not just the relative numbers.\u003c\/p\u003e\n\u003cp\u003eHere's a concrete example used in the original article. Imagine that lowering blood pressure by 10\/5 mmHg produces a 20% relative risk reduction for major cardiovascular events. Now consider two different patients:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatient 1:\u003c\/strong\u003e A 50-year-old, non-smoking, non-diabetic African-American woman with total cholesterol of 190 mg\/dL, HDL (good) cholesterol of 45 mg\/dL, and systolic blood pressure of 135 mmHg. Her predicted 10-year risk of a major cardiovascular event is 3%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatient 2:\u003c\/strong\u003e A 50-year-old, diabetic African-American woman who smokes, has total cholesterol of 200 mg\/dL, HDL cholesterol of 35 mg\/dL, and systolic blood pressure of 135 mmHg. Her predicted 10-year risk of a major cardiovascular event is 20%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBoth patients get a 20% relative risk reduction from treatment. But the actual benefit they experience is very different:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePatient 1's risk drops from 3% to 2.4% — an \u003cstrong\u003eabsolute risk reduction of only 0.6%\u003c\/strong\u003e. In a group of patients like her, \u003cstrong\u003e167 people\u003c\/strong\u003e would need to take blood pressure medication for 10 years to prevent one heart attack, stroke, or other major event.\u003c\/li\u003e\n  \u003cli\u003ePatient 2's risk drops from 20% to 16% — an \u003cstrong\u003eabsolute risk reduction of 4.0%\u003c\/strong\u003e. In a group of patients like her, only \u003cstrong\u003e25 people\u003c\/strong\u003e would need to take medication for 10 years to prevent one event.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis example shows that the same treatment can have very different real-world value depending on your starting risk. The higher your baseline risk, the more you stand to gain from treatment.\u003c\/p\u003e\n\u003cp\u003eThis concept is backed by research. A 2014 meta-analysis of 11 randomized trials comparing antihypertensive therapy with placebo looked at patients stratified by their estimated 5-year risk of major cardiovascular events (heart attack, stroke, or heart failure), using age, sex, body mass index, prior history of cardiovascular disease, smoking, and diabetes status. The results showed:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eIn patients with the \u003cstrong\u003ehighest\u003c\/strong\u003e cardiovascular risk (5-year risk greater than 21%), the absolute risk reduction from treatment was \u003cstrong\u003e3.8%\u003c\/strong\u003e, meaning 26 patients needed to be treated for 5 years to prevent one event.\u003c\/li\u003e\n  \u003cli\u003eIn patients with the \u003cstrong\u003elowest\u003c\/strong\u003e risk (5-year risk of about 6%), the absolute risk reduction was \u003cstrong\u003e1.4%\u003c\/strong\u003e, meaning 71 patients needed treatment for 5 years to prevent one event.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe relative risk reduction was similar across all risk levels, but the absolute benefit was much larger for high-risk patients. This is why doctors weigh your personal risk profile so heavily when deciding how aggressively to treat your blood pressure.\u003c\/p\u003e\n\n\u003ch2 id=\"higher-risk\"\u003eBlood Pressure Goals for Higher-Risk Patients\u003c\/h2\u003e\n\u003cp\u003eThe experts recommend more aggressive (lower) blood pressure targets for patients who are at higher risk for future cardiovascular events. You are considered higher-risk if you have one or more of the following characteristics:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eEstablished atherosclerotic cardiovascular disease (prior history of coronary disease, prior stroke or transient ischemic attack [TIA, sometimes called a \"mini-stroke\"], or documented peripheral arterial disease)\u003c\/li\u003e\n  \u003cli\u003eHeart failure\u003c\/li\u003e\n  \u003cli\u003eDiabetes mellitus\u003c\/li\u003e\n  \u003cli\u003eChronic kidney disease (CKD)\u003c\/li\u003e\n  \u003cli\u003eAge over 65 years\u003c\/li\u003e\n  \u003cli\u003eMultiple cardiovascular risk factors with an estimated 10-year risk of future cardiovascular events of 10% or greater (your doctor can calculate this with a risk calculator)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePatients without any of these characteristics are considered lower-risk, and a less intensive goal is recommended for them.\u003c\/p\u003e\n\u003ch3\u003ePatients with Established Atherosclerotic Cardiovascular Disease\u003c\/h3\u003e\n\u003cp\u003eFor patients with established atherosclerotic cardiovascular disease (a prior history of coronary artery disease, cerebrovascular disease, or peripheral arterial disease), the experts recommend a goal blood pressure of \u003cstrong\u003e120 to 125\/\u0026lt;80 mmHg\u003c\/strong\u003e when measured using the preferred \"non-routine\" methods (standardized office measurement, AOBPM, home blood pressure monitoring, or ABPM). If routine office measurements are used, the goal is slightly higher: \u003cstrong\u003e125 to 130\/\u0026lt;80 mmHg\u003c\/strong\u003e. This accounts for the fact that routine measurements tend to run 5–15 mmHg higher.\u003c\/p\u003e\n\u003cp\u003eThe strongest evidence supporting this target comes from the SPRINT trial, which is described in detail below.\u003c\/p\u003e\n\n\u003ch2 id=\"sprint\"\u003eThe SPRINT Trial: Key Evidence for Intensive Blood Pressure Control\u003c\/h2\u003e\n\u003cp\u003eThe Systolic Blood Pressure Intervention Trial (SPRINT) is one of the most important studies ever conducted on blood pressure treatment. It was a large, multicenter, randomized, open-label trial performed in the United States, and its findings have shaped how doctors treat hypertension in higher-risk patients.\u003c\/p\u003e\n\u003ch3\u003eWho Was Enrolled in SPRINT?\u003c\/h3\u003e\n\u003cp\u003eSPRINT enrolled \u003cstrong\u003e9,361 patients aged 50 years or older\u003c\/strong\u003e. More than 90% were already taking antihypertensive medication at the start of the trial. To be included, patients needed a systolic blood pressure of 130 to 180 mmHg plus at least one of the following additional risk factors:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAge 75 years or older\u003c\/li\u003e\n  \u003cli\u003eClinically evident cardiovascular disease (previously documented coronary, peripheral arterial, or cerebrovascular disease, except stroke)\u003c\/li\u003e\n  \u003cli\u003eSubclinical cardiovascular disease (elevated coronary artery calcification score on a CT scan, left ventricular hypertrophy, or an ankle-brachial index below 0.9)\u003c\/li\u003e\n  \u003cli\u003eEstimated glomerular filtration rate (eGFR) of 20 to 59 mL\/min\/1.73 m² (indicating moderately reduced kidney function)\u003c\/li\u003e\n  \u003cli\u003e10-year Framingham Risk Score of 15% or greater\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSPRINT excluded patients with diabetes, symptomatic heart failure, a history of stroke, or proteinuria (1 g\/day or more of total protein or 600 mg\/day or more of albumin in the urine). Nursing home residents were also excluded.\u003c\/p\u003e\n\u003ch3\u003eBaseline Characteristics of SPRINT Participants\u003c\/h3\u003e\n\u003cp\u003eAt the start of the trial, the average age of participants was \u003cstrong\u003e68 years\u003c\/strong\u003e, the average body mass index (BMI) was \u003cstrong\u003e30 kg\/m²\u003c\/strong\u003e, the average Framingham 10-year risk score was \u003cstrong\u003e20%\u003c\/strong\u003e, and the average blood pressure was \u003cstrong\u003e140\/78 mmHg\u003c\/strong\u003e. Clinical or subclinical cardiovascular disease was present in \u003cstrong\u003e22%\u003c\/strong\u003e of patients.\u003c\/p\u003e\n\u003ch3\u003eHow the Trial Was Conducted\u003c\/h3\u003e\n\u003cp\u003ePatients were randomly assigned to one of two treatment groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStandard treatment group:\u003c\/strong\u003e targeting systolic blood pressure to \u0026lt;140 mmHg\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntensive treatment group:\u003c\/strong\u003e targeting systolic blood pressure to \u0026lt;120 mmHg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn both groups, the diastolic blood pressure goal was \u0026lt;90 mmHg. Blood pressure during the trial was measured using attended or unattended AOBPM, the preferred standardized method discussed earlier.\u003c\/p\u003e\n\u003cp\u003eTreatment typically started with an ACE inhibitor (angiotensin-converting enzyme inhibitor) or an ARB (angiotensin receptor blocker) — but never both — a long-acting calcium channel blocker (usually amlodipine), or a thiazide-like diuretic (specifically chlorthalidone rather than hydrochlorothiazide), or a combination of these medications. Additional drugs were added as needed to reach the target.\u003c\/p\u003e\n\u003cp\u003eImportantly, in the standard treatment group, medications were actively withdrawn if systolic blood pressure fell below 130 to 135 mmHg, even if the patient felt fine. In both groups, medications were adjusted or stopped if adverse effects developed.\u003c\/p\u003e\n\u003cp\u003eWhat happened in the first year? About \u003cstrong\u003ehalf of the patients in the intensive-treatment group attained a systolic pressure below 120 mmHg\u003c\/strong\u003e. The average systolic pressures at one year were \u003cstrong\u003e121 mmHg\u003c\/strong\u003e in the intensive group and \u003cstrong\u003e136 mmHg\u003c\/strong\u003e in the standard group. The average number of antihypertensive medications used was \u003cstrong\u003e2.8\u003c\/strong\u003e in the intensive group and \u003cstrong\u003e1.8\u003c\/strong\u003e in the standard group.\u003c\/p\u003e\n\n\u003ch2 id=\"sprint-results\"\u003eWhat the SPRINT Results Show\u003c\/h2\u003e\n\u003cp\u003eThe trial was halted early for benefit after a median follow-up of \u003cstrong\u003e3.33 years\u003c\/strong\u003e — in other words, the benefits of intensive treatment were so clear that the researchers felt it was no longer ethical to continue having the standard group follow the less intensive target. Here are the key findings:\u003c\/p\u003e\n\u003ch3\u003eMajor Benefits of Intensive Blood Pressure Control\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrimary endpoint reduced:\u003c\/strong\u003e The primary endpoint was a combination (composite) of heart attack (myocardial infarction), acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes. This occurred in \u003cstrong\u003e5.6%\u003c\/strong\u003e of the intensive group compared with \u003cstrong\u003e7.6%\u003c\/strong\u003e of the standard group — a significant reduction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeart failure reduced:\u003c\/strong\u003e Rates were \u003cstrong\u003e1.4%\u003c\/strong\u003e in the intensive group versus \u003cstrong\u003e2.2%\u003c\/strong\u003e in the standard group.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeart attacks reduced:\u003c\/strong\u003e Rates were \u003cstrong\u003e2.2%\u003c\/strong\u003e versus \u003cstrong\u003e3.0%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCardiovascular deaths reduced:\u003c\/strong\u003e Rates were \u003cstrong\u003e0.9%\u003c\/strong\u003e versus \u003cstrong\u003e1.5%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall mortality reduced:\u003c\/strong\u003e Death from any cause was \u003cstrong\u003e3.5%\u003c\/strong\u003e in the intensive group versus \u003cstrong\u003e4.6%\u003c\/strong\u003e in the standard group.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBenefits in patients with known cardiovascular disease:\u003c\/strong\u003e Among those with heart or blood vessel disease at baseline, the primary endpoint occurred in \u003cstrong\u003e11.0%\u003c\/strong\u003e of the intensive group versus \u003cstrong\u003e13.3%\u003c\/strong\u003e of the standard group, although this difference was not statistically significant (meaning it could have been due to chance).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eBrain Health Benefits\u003c\/h3\u003e\n\u003cp\u003eIntensive blood pressure control also showed benefits for the brain. Over a median follow-up of \u003cstrong\u003e5.1 years\u003c\/strong\u003e, intensive treatment \u003cstrong\u003ereduced the rate of mild cognitive impairment\u003c\/strong\u003e (6.1% versus 7.5%). It also \u003cstrong\u003ereduced the accumulation of cerebral white matter lesions\u003c\/strong\u003e — small areas of brain damage visible on MRI scans that are associated with cognitive decline and stroke risk.\u003c\/p\u003e\n\u003cp\u003eThere was no increase in the development of dementia in the intensive group. Notably, there were also \u003cstrong\u003eno differences between treatment groups\u003c\/strong\u003e in physical and mental health-related quality of life, symptoms of depression, or satisfaction with care.\u003c\/p\u003e\n\u003ch3\u003eSide Effects and Safety Considerations\u003c\/h3\u003e\n\u003cp\u003eIntensive treatment was not without risks. The following side effects occurred more frequently in the intensive group:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAcute kidney injury (AKI):\u003c\/strong\u003e Occurred in \u003cstrong\u003e3.8%\u003c\/strong\u003e of the intensive group versus \u003cstrong\u003e2.3%\u003c\/strong\u003e of the standard group. However, in the majority of patients, the AKI was mild — \u003cstrong\u003e61%\u003c\/strong\u003e had stage 1 AKI and \u003cstrong\u003e17%\u003c\/strong\u003e had stage 2. Importantly, about \u003cstrong\u003e95%\u003c\/strong\u003e of AKI cases completely or partially resolved. Mild to moderate AKI typically doesn't require reducing blood pressure medication unless hyperkalemia (high potassium) is also present.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNew chronic kidney disease (CKD):\u003c\/strong\u003e Defined as a substantive decline in eGFR from ≥60 to \u0026lt;60 mL\/min\/1.73 m², new CKD developed in \u003cstrong\u003e3.7%\u003c\/strong\u003e of the intensive group versus \u003cstrong\u003e1.0%\u003c\/strong\u003e of the standard group. However, this increase in creatinine (a waste product used to measure kidney function) during intensive blood pressure lowering is thought to reflect a benign, functional, and reversible change in GFR due to reduced blood flow rather than actual kidney damage. In fact, levels of kidney injury biomarkers were \u003cem\u003elower\u003c\/em\u003e, not higher, in the intensive group, supporting this interpretation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFainting (syncope):\u003c\/strong\u003e Occurred in \u003cstrong\u003e3.2%\u003c\/strong\u003e of the intensive group versus \u003cstrong\u003e2.1%\u003c\/strong\u003e of the standard group.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow blood sodium (hyponatremia):\u003c\/strong\u003e Occurred in \u003cstrong\u003e4.0%\u003c\/strong\u003e of the intensive group versus \u003cstrong\u003e2.2%\u003c\/strong\u003e of the standard group.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eReassuringly, the rates of \u003cstrong\u003einjurious falls\u003c\/strong\u003e (falls serious enough to require emergency department evaluation or hospitalization) were \u003cstrong\u003esimilar between the two groups\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\u003cp\u003eWhat does this all mean for you? The findings from SPRINT suggest that, among older, hypertensive, non-diabetic adults who are at high risk for cardiovascular disease, targeting systolic blood pressure to below 120 mmHg (measured with AOBPM) can \u003cstrong\u003ereduce mortality and prevent serious cardiovascular events\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe authors of the original article note that lower blood pressure targets in higher-risk groups are relevant to a large segment of the population. Pursuing more intensive blood pressure lowering in such patients is likely to be \u003cstrong\u003ecost effective\u003c\/strong\u003e, even though it requires more medication and additional monitoring.\u003c\/p\u003e\n\u003cp\u003eThere are strong data supporting treatment decisions in certain patient populations, including patients with severely elevated blood pressure (for example, diastolic pressure of ≥110 mmHg), patients at high cardiovascular risk, and older adults. However, the data are weaker and largely indirect for many other patient populations. This is why your doctor will use good clinical judgment and engage in \u003cstrong\u003eshared decision-making\u003c\/strong\u003e with you — meaning you work together to weigh the potential benefits and risks of more intensive treatment based on your individual circumstances.\u003c\/p\u003e\n\u003cp\u003eThe authors also emphasize that the more aggressive goals apply specifically to higher-risk patients. For lower-risk patients, a less intensive goal is appropriate, because the absolute benefit of very aggressive treatment is smaller while the inconvenience, cost, and potential for side effects remain.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Research Couldn't Prove\u003c\/h2\u003e\n\u003cp\u003eWhile SPRINT was a landmark trial, the authors are careful to point out several factors that may affect how its findings apply to real-world patients:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients in SPRINT were healthier than typical patients:\u003c\/strong\u003e Many patients in the trial had controlled blood pressure at baseline. In general, people who enroll in clinical trials are healthier than other patients with the same condition. This means the rate of side effects reported in SPRINT may be an \u003cem\u003eunderestimate\u003c\/em\u003e of what happens when intensive treatment is used in routine practice, where patients often have more health problems.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore medications may be needed:\u003c\/strong\u003e Patients in routine practice may require more blood pressure medications than SPRINT participants did. The average was about \u003cstrong\u003ethree\u003c\/strong\u003e medications in the intensive treatment group, and about \u003cstrong\u003eone-fourth required four or more\u003c\/strong\u003e. Taking more medications could increase the risk of side effects.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMeasurement method differences:\u003c\/strong\u003e Blood pressure in SPRINT was measured using AOBPM (attended and unattended), which corresponds more closely with mean daytime blood pressure (from 24-hour ambulatory monitoring) than with the casual, routine office measurements typically performed in practice. Since routine measurements tend to be 5–15 mmHg higher, the goals in SPRINT don't translate directly to routine office readings. This is why the recommended goals are higher (125–130 mmHg) when routine office measurement is used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiabetes and other conditions excluded:\u003c\/strong\u003e SPRINT excluded patients with diabetes, symptomatic heart failure, and stroke. Other trials provide guidance for those populations (the ACCORD trial, which studied intensive blood pressure control in people with diabetes, used similar AOBPM methodology), but the authors note that blood pressure goal trials using home blood pressure measurement or ABPM are lacking.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePopulation vs. individual differences:\u003c\/strong\u003e The 5–15 mmHg difference between routine and non-routine measurement is an average across populations. Individual patients may not follow this pattern, and some don't experience a white coat effect at all. This creates uncertainty when setting goals for any given person.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003eBased on the expert guidelines and the research reviewed here, here are actionable steps you can discuss with your healthcare provider:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the preferred measurement method.\u003c\/strong\u003e Ask your doctor whether your blood pressure can be measured using one of the standardized preferred methods — standardized office-based measurement (with proper rest and technique), AOBPM, home blood pressure monitoring, or 24-hour ambulatory monitoring. These give a more accurate picture than a quick reading at the start of an appointment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider home blood pressure monitoring.\u003c\/strong\u003e If you monitor at home, take 2–4 readings daily for 5–7 days before your clinic visit, using a properly validated automated device. Bring your average readings to your appointment. Use proper technique: sit quietly for 5 minutes with both feet on the floor, no talking, correct cuff size, and empty bladder.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your risk level.\u003c\/strong\u003e Ask your doctor to calculate your 10-year risk of cardiovascular events. If you have a 10-year risk of 10% or higher — or if you have established heart or blood vessel disease, heart failure, diabetes, chronic kidney disease, or are over 65 — you may benefit from a more intensive blood pressure goal.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your target number.\u003c\/strong\u003e If you are a higher-risk patient, your goal may be around \u003cstrong\u003e120–125\/\u0026lt;80 mmHg\u003c\/strong\u003e using preferred measurement methods, or \u003cstrong\u003e125–130\/\u0026lt;80 mmHg\u003c\/strong\u003e using routine office measurements. If you are lower-risk, a less intensive goal is appropriate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect a combination of medications.\u003c\/strong\u003e Reaching lower blood pressure goals often requires more than one medication — the average in SPRINT's intensive group was about three drugs. This is normal and expected; don't be discouraged if you need multiple medications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWatch for side effects.\u003c\/strong\u003e More intensive blood pressure lowering can cause dizziness, fainting, low sodium, or changes in kidney function tests. While the vast majority of these issues resolve, you should report any concerning symptoms to your doctor promptly. The risk of serious falls was \u003cem\u003enot\u003c\/em\u003e increased in SPRINT, which is reassuring.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe an active participant.\u003c\/strong\u003e Because the evidence is strong for some patient groups but weaker for others, shared decision-making with your doctor is essential. Discuss your personal values, lifestyle, medication tolerability, and preferences. A goal that works well for one person may not be right for another.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe bottom line: blood pressure treatment saves lives, and more intensive treatment can provide substantial additional benefits for patients at higher risk. The key is to use accurate measurement methods, know your personal risk, and work with your doctor to find the target that gives you the best balance of benefit and safety.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the difference between routine and standardized blood pressure measurement?\u003c\/h3\u003e\n\u003cp\u003eRoutine office readings are taken quickly, without strict preparation, and can run 5–15 mmHg higher than preferred methods. Standardized approaches—such as automated devices, home monitoring, or 24-hour ambulatory monitoring—require rest and proper technique, giving readings closer to your true daytime blood pressure. Doctors prefer these for setting treatment goals.\u003c\/p\u003e\n\u003ch3\u003eWhy might my doctor recommend a lower blood pressure target for me?\u003c\/h3\u003e\n\u003cp\u003eLower targets are advised for people at higher risk of heart attacks, strokes, or heart failure. This includes those with established heart or blood vessel disease, diabetes, chronic kidney disease, heart failure, age over 65, or a 10-year risk score of 10% or higher. For lower-risk patients, a less intensive goal is appropriate because absolute benefit is smaller.\u003c\/p\u003e\n\u003ch3\u003eWhat did the SPRINT trial show about intensive blood pressure control?\u003c\/h3\u003e\n\u003cp\u003eIn SPRINT, over 9,300 high-risk adults aged 50+ without diabetes were randomly assigned to a systolic target below 120 or below 140 mmHg. Intensive treatment significantly reduced heart attacks, heart failure, cardiovascular deaths, and overall mortality. It also lowered mild cognitive impairment and brain white matter lesions. The trial was halted early for clear benefit.\u003c\/p\u003e\n\u003ch3\u003eWhat are the potential side effects of intensive blood pressure lowering?\u003c\/h3\u003e\n\u003cp\u003eIn the SPRINT trial, intensive treatment increased rates of acute kidney injury, new chronic kidney disease, fainting, and low blood sodium compared with standard treatment. Most kidney issues were mild and resolved or partially resolved. Serious injurious falls were not increased. If you experience dizziness, fainting, or other symptoms, tell your doctor promptly.\u003c\/p\u003e\n\u003ch3\u003eHow should I measure my blood pressure at home?\u003c\/h3\u003e\n\u003cp\u003eUse a validated automated device. Take 2–4 readings daily for 5–7 days before your clinic visit, then average them. Sit quietly for 5 minutes with both feet on the floor, no talking, use the correct cuff size, and empty your bladder first. Bring these averages to your appointment to help guide treatment decisions.\u003c\/p\u003e\n\u003ch3\u003eWhat is the difference between absolute and relative risk reduction?\u003c\/h3\u003e\n\u003cp\u003eRelative risk reduction is the percentage by which treatment lowers your chance of an event. Absolute risk reduction is the actual percentage-point drop in your personal risk. For example, a 20% relative reduction may mean only a 0.6% absolute benefit in a low-risk patient but a 4.0% benefit in a high-risk patient. Your doctor uses absolute benefit to decide treatment intensity.\u003c\/p\u003e\n\u003ch3\u003eWhat blood pressure goal is recommended for patients with established heart or blood vessel disease?\u003c\/h3\u003e\n\u003cp\u003eFor these higher-risk patients, experts recommend a goal of 120–125\/\u0026lt;80 mmHg when measured with preferred standardized methods, such as automated or home monitoring. If routine office measurements are used, the goal is slightly higher: 125–130\/\u0026lt;80 mmHg. This accounts for the tendency of routine readings to be 5–15 mmHg higher.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Goal blood pressure in adults with hypertension - UpToDate\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Johannes FE Mann, MD, and Karl F Hilgers, MD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSection editors:\u003c\/strong\u003e George L Bakris, MD; William B White, MD; Scott E Kasner, MD; David M Nathan, MD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDeputy editors:\u003c\/strong\u003e John P Forman, MD, MSc; Karen Law, MD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e UpToDate, literature review current through April 2023; topic last updated February 8, 2023. The article includes the SPRINT trial (Systolic Blood Pressure Intervention Trial) and a 2014 meta-analysis of 11 randomized trials as key evidence.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eNote: This patient-friendly article is based on peer-reviewed research and expert clinical guidelines. It is provided for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with questions about your blood pressure management.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47457933525148,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.it\/products\/understanding-your-blood-pressure-goal-a-patients-guide-to-hypertension-treatment-targets","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}